Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00293280
Recruitment Status : Completed
First Posted : February 17, 2006
Last Update Posted : May 6, 2013
National Cancer Institute (NCI)
Information provided by:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well lomustine works in treating patients with stage III or stage IV non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: lomustine Phase 2

Detailed Description:



  • Evaluate the response rate to lomustine in patients with stage IIIB or IV non-small cell lung cancer with aberrant methylation of the MGMT gene.
  • Determine whether the response rate in these patients is significantly greater than that of the historical control.


  • Collect preliminary data on toxicity, disease stabilization, time to disease progression, and overall survival.


  • Evaluate the association between clinical outcome and immunohistochemical staining by grouping the patients as complete or partial loss of MGMT gene.

OUTLINE: This is a multicenter study.

Patients receive oral lomustine once on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene
Study Start Date : July 2005
Actual Primary Completion Date : July 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Lomustine
U.S. FDA Resources

Primary Outcome Measures :
  1. Response rate

Secondary Outcome Measures :
  1. Toxicity
  2. Disease stabilization
  3. Time to disease progression
  4. Overall survival
  5. Association between clinical outcome and immunohistochemical staining

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed non-small cell bronchogenic carcinoma, including the following histologic subtypes:

    • Squamous cell
    • Adenocarcinoma
    • Adenosquamous
    • Large cell anaplastic
    • Bronchoalveolar
    • Non-small cell carcinoma not otherwise specified (NOS)
  • Stage IIIB disease (with a pleural effusion) or stage IV disease

    • Stage IV patients with brain metastases are eligible provided the brain metastases are clinically stable after treatment with surgery and/or radiation therapy
  • Tumors must test positive for aberrant methylation of the MGMT gene by methylation-specific polymerase chain reaction
  • Bidimensionally measurable or evaluable disease


  • ECOG performance status 0-2
  • No other active malignancies
  • WBC ≥ 4,000/mm^3 OR absolute neutrophil count ≥ 2,000/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Total bilirubin normal
  • AST < 5 times upper limit of normal
  • Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
  • No uncontrolled serious active infection
  • Not pregnant or nursing


  • See Disease Characteristics
  • More than 3 weeks since prior chemotherapy
  • No more than 2 prior chemotherapy regimens
  • No prior therapy with nitrosoureas
  • Recovered from prior radiation therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00293280

United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Study Chair: Julie Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Identifier: NCT00293280     History of Changes
Other Study ID Numbers: JHOC-J0336, CDR0000452787
P30CA006973 ( U.S. NIH Grant/Contract )
First Posted: February 17, 2006    Key Record Dates
Last Update Posted: May 6, 2013
Last Verified: May 2013

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
stage IIIB non-small cell lung cancer
stage IV non-small cell lung cancer
adenocarcinoma of the lung
adenosquamous cell lung cancer
bronchoalveolar cell lung cancer
large cell lung cancer
recurrent non-small cell lung cancer
squamous cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents